SMLR Research | Milton Maxwell

SMLR

Semler Scientific, Inc.

17.40

+1.37+8.55%

Dec 16, 4:00:01 PM EST

Upcoming Earnings

Report date

≈ -/-

Earnings Call Transcripts

This Quarter (Q1 '26)

No earnings call transcript available yet

Last Quarter (Q4 '25)

No earnings call transcript available

Key Stats

Market Cap

265.96M

P/E (TTM)

3.36

Basic EPS (TTM)

5.18

Dividend Yield

Recent Filings

8-K

Strive acquires Semler

1/16/26Jan 16, 2026

Strive completed its acquisition of Semler Scientific on January 16, 2026, via merger, converting each Semler share into 21.05 Strive Class A shares. Semler survives as Strive's wholly owned subsidiary, with Nasdaq delisting set for January 20. A supplemental indenture adjusts Semler's $100.0 million 4.25% notes due 2030 for Strive stock conversion at 275.3887 shares per $1,000, backed by Strive guarantee. Change in control locks in.

8-K

Merger approved by shareholders

1/13/26Jan 13, 2026

Semler Scientific stockholders approved the merger with Strive, Inc. on January 13, 2026, with 8.7M votes for versus 634K against on the merger proposal. The advisory compensation vote passed narrowly at 5.7M for. Merger awaits closing amid Bitcoin volatility risks and integration hurdles.

8-K

37% headcount reduction announced

12/12/25Dec 12, 2025

Semler Scientific approved a 37% headcount cut and expense curbs on December 12, 2025, to boost operating leverage ahead of its pending Strive merger. This targets $0.7-$1.1 million quarterly base salary savings starting January 2026, offset by $1.2 million severance and $1.6 million non-executive retention costs. Savings hinge on assumptions; actuals may differ.

8-K

Pro forma merger financials filed

11/14/25Nov 14, 2025

Semler Scientific filed supplemental unaudited pro forma combined financials for its pending all-stock merger with Strive, announced September 22, 2025, converting each Semler share into 21.05 Strive Class A shares. Pro formas show combined assets of $1.4B as of September 30, 2025, driven by $1.2B digital assets, yet nine-month net loss of $200M. Strive leads as accounting acquirer. Closing risks persist.

10-Q

Q3 FY2025 results

11/12/25Nov 12, 2025

Semler Scientific's Q3 revenues fell 45% y/y to $7.5M, reflecting customer pullbacks from CMS reimbursement shifts and DOJ settlement, while operating loss hit $5.4M versus $5.1M profit last year amid DOJ expense timing. Yet Bitcoin fair value gains of $28.5M drove net income to $16.9M ($1.07 diluted EPS), with shares up to 16.5M from convertibles. Cash sits at $10.2M; $100M 4.25% notes due 2030 and $20M Coinbase loan (10%, Bitcoin-collateralized, due Mar 2026) fund Bitcoin buys to 4,733 coins. Merger with Strive pending. Bitcoin volatility swings results.

About

Semler Scientific, Inc. provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. The company's products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, family practitioners, healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups and retailers. It offers its products through sales representatives and distributors. The company was incorporated in 2007 and is headquartered in Santa Clara, California.

CEO

Mr. Eric H. Semler

IPO

2/21/2014

Website

https://www.semlerscientific.com

Employees

Sector

Healthcare

Industry

Medical Devices